Sengenics
Sengenics is a Functional Proteomics company focused on leveraging its core patented KREX» technology for developing new diagnostic tests and therapies for Human disease. The fundamental research for KREX» was led by Professor Jonathan Blackburn as a collaboration between Oxford and Cambridge University in the late 1990s. The uniqueness of the KREX» technology stems from the fact that every protein is correctly folded and functional. Every protein on the array is cloned in frame with the BCCP folding marker. Misfolded proteins will not become biotinylated and are washed away. Only correctly folded proteins are biotinylated and immobilised on the array. Key applications of the KREX» technology are autoantibody biomarker discovery, cancer immunotherapy, predicting vaccine responsiveness and infectious diseases diagnostics. Sengenics has commercial operations with state-of-the-art proteomics laboratory and production facilities in Singapore, the UK and South Africa. Sengenics has forged mutually beneficial strategic corporate and academic collaborations with some of the worldÍs top pharmaceutical companies, world-class universities and leading research institutions by offering solutions in three categories: Standard array format, custom array format and the Immunome Technology Access Program (iTAP). The company has 15 granted patents in the USA, UK, EU, Japan, Canada and Australia. Sengenics also has IP positions on diagnostics, therapeutics and screening of eleven Human diseases ranging from Cancers, Autoimmune disorders, Vaccines, Cancer Immunotherapy and Transplantation rejection screening.
Biotechnology
50 - 200
Singapore, Singapore, Singapore
About

Sengenics is a Functional Proteomics company focused on leveraging its core patented KREX» technology for developing new diagnostic tests and therapies for Human disease. The fundamental research for KREX» was led by Professor Jonathan Blackburn as a collaboration between Oxford and Cambridge University in the late 1990s.

The uniqueness of the KREX» technology stems from the fact that every protein is correctly folded and functional. Every protein on the array is cloned in frame with the BCCP folding marker. Misfolded proteins will not become biotinylated and are washed away. Only correctly folded proteins are biotinylated and immobilised on the array. Key applications of the KREX» technology are autoantibody biomarker discovery, cancer immunotherapy, predicting vaccine responsiveness and infectious diseases diagnostics.

Sengenics has commercial operations with state-of-the-art proteomics laboratory and production facilities in Singapore, the UK and South Africa.

Sengenics has forged mutually beneficial strategic corporate and academic collaborations with some of the worldÍs top pharmaceutical companies, world-class universities and leading research institutions by offering solutions in three categories: Standard array format, custom array format and the Immunome Technology Access Program (iTAP). The company has 15 granted patents in the USA, UK, EU, Japan, Canada and Australia. Sengenics also has IP positions on diagnostics, therapeutics and screening of eleven Human diseases ranging from Cancers, Autoimmune disorders, Vaccines, Cancer Immunotherapy and Transplantation rejection screening.

Site Traffic
  • 5943613 Global Rank
  • 1719717
    United States
Traffic Sources
  • Search
    80.55%
  • Direct
    19.45%
  • Display
    0.00%
  • Mail
    0.00%
  • Referrals
    0.00%
  • Social
    0.00%
Powered by
Alexa Traffic Data
Global Rank 884,664
11,124
Malaysia Rank 9,679
8,167
Malaysia Page Views 100.0%
0.9%
Top Countries
Top Search Keywords
  • Coral Springs
Ad Intelligence
  • Native
    0%
  • Standard
    0%
Ads Seen Recently
0
Longest Running Ad
Sengenics
Device
Desktop
Dimensions
none
They are headquartered at Singapore, Singapore, Singapore, and have 1 advertising & marketing contacts listed on Kochava. Sengenics works with Advertising technology companies such as LinkedIn Ads, DoubleClick.Net, Bizo, Google Remarketing.